Analyst recommendations: Illumina, Freeport-McMoran, XPO, T-Mobile US…

Every morning, find a selection of analysts' recommendations covering North America and the UK. The list only includes companies that have been the subject of a change of opinion or price target, or of a new coverage. It may be updated during the session. This information can be used to shed light on movements in certain stocks or on market sentiment towards a company.

• Illumina. – Citi cut its rating to Sell from Neutral; PT $80, implying -19% downside.
• Charles River Laboratories International – Citi raised its rating to Buy from Neutral; PT $200, implying +26% upside.
• Freeport-McMoRan. – Stifel Canada initiated coverage with a Buy rating; PT $56, implying +21% upside.
• Newmont  – Stifel Canada initiated coverage with a Buy rating; PT $73, implying +27% upside.
• Hologic – Citi raised its rating to Buy from Neutral; PT $80, implying +23% upside.
• XPO – Citi cut its rating to Neutral from Buy; PT $140, implying +5.9% upside.
• Altria Group Jefferies reinstated coverage at Underperform; PT $50, implying -16% downside.
• Philip Morris International Inc. – Jefferies reinstated coverage at Buy; PT $220, implying +24% upside.
• EOG Resources  – Roth Capital Partners cut its rating to Neutral from Buy; PT $134, implying +8.1% upside.
• T-Mobile US – KeyBanc Capital Markets cut its rating to Underweight from Sector Weight; PT $200, implying -15% downside.
• Hanover Insurance Group – Keefe, Bruyette & Woods raised its rating to Outperform from Market Perform; price target (PT) $188, implying +15% upside.